DD
The startup develops RNA-targeting genetic therapies using proprietary gene silencing technology to reduce target gene expression, offering a potential long-term treatment option for rare inherited diseases. This approach aims to provide patients with the possibility of a single course of therapy, addressing the lack of effective treatments for these conditions.
Updated 3 months ago
Funding
$310K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops RNA-targeting genetic therapies using proprietary gene silencing technology to reduce target gene expression, offering a potential long-term treatment option for rare inherited diseases. This approach aims to provide patients with the possibility of a single course of therapy, addressing the lack of effective treatments for these conditions.